Cybin Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric So
- Full Time Employees
- 50
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 King Street West Toronto ON Canada M5X 1C9
- IPO Date
- Sep 13, 2019
- CIK
- 0001833141
- Website
- cybin.com
- Similar Companies
- Business
- Cybin Inc. is a clinical-stage neuropsychiatry company that develops proprietary psychedelic-based therapeutics, including tryptamine serotonin receptor agonists, to treat mental health conditions such as major depressive disorder, generalized anxiety disorder and central nervous system disorders; its lead candidates comprise CYB003, a deuterated psilocin analog in Phase 3 trials as an adjunctive treatment for major depressive disorder, CYB004, a deuterated DMT molecule in Phase 2 for generalized anxiety disorder, and CYB005, an early-stage program targeting CNS disorders, supported by proprietary drug discovery platforms, innovative delivery systems and novel formulations with over 100 granted patents and 250 pending applications. The company engineers next-generation therapies based on psilocin, DMT and MDMA scaffolds with enhanced bioavailability alongside facilitation training programs to advance mental health treatments. Founded in 2019 and headquartered in Toronto, Canada, Cybin operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland, targeting patients with unmet needs in neuropsychiatry through intermittent dosing regimens for sustained efficacy. Recently, Cybin completed enrollment in its Phase 2 study of CYB004 for generalized anxiety disorder, reported positive Phase 2 data for CYB003 demonstrating 12-month efficacy in major depressive disorder, received FDA Breakthrough Therapy Designation for CYB003 with supportive four-month durability data, launched the multinational PARADIGM Phase 3 program for CYB003 comprising APPROACH, EMBRACE and EXTEND studies targeting 550 patients, established strategic clinical site partnerships including with Segal Trials, engaged Thermo Fisher Scientific for U.S. manufacturing of CYB003 drug substance and product, partnered with Osmind to leverage its 800-clinic network for commercial preparation, and announced a $175 million registered direct offering to fund clinical milestones. These advancements build on its 2024 accomplishments, including pipeline progression and clinical expertise expansion, positioning the company for potential transformation of the mental health treatment landscape.
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
Psychedelics stocks rise after Trump order expands research, access pathways
Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript
Cybin (OTCMKTS:CYBN) Stock Price Up 1.2% – Here’s Why
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
Cybin (NYSEAMERICAN:CYBN) Stock Price Up 4.4% – Should You Buy?
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
Cybin (NYSEAMERICAN:CYBN) Trading Down 8.2% – Here’s Why
Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
Cybin to Participate in the Jefferies Global Healthcare Conference in London
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
Cybin Announces Closing of $175 Million Registered Direct Offering
Cybin Announces $175 Million Registered Direct Offering
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN